First Light Asset Management’s Keros Therapeutics KROS Stock Holding History

First Light Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-421,438	Closed	-$13.4M	–	78
2023 Q3	$13.4M	Buy	421,438 +4,608	+1%	+$172K	1.28%	30
2023 Q2	$16.7M	Sell	416,830 -177,134	-30%	-$7.77M	1.31%	27
2023 Q1	$25.4M	Buy	593,964 +1,552	+0.3%	+$78.4K	2.28%	17
2022 Q4	$28.4M	Sell	592,412 -5,801	-1%	-$271K	2.64%	11
2022 Q3	$22.5M	Sell	598,213 -120	-0%	-$4.16K	2.28%	18
2022 Q2	$16.5M	Sell	598,333 -59,812	-9%	-$2.62M	1.92%	20
2022 Q1	$35.8M	Buy	658,145 +106,047	+19%	+$5.44M	3.16%	11
2021 Q4	$32.3M	Buy	552,098 +378,888	+219%	+$18.9M	2.31%	16
2021 Q3	$6.85M	Buy	+173,210	New	+$6.16M	0.45%	47

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Light Asset Management's KROS Position: Q4 2023 in Review

First Light Asset Management sold out of Keros Therapeutics (KROS) in Q4 2023, closing a stake of 421,438 shares — an estimated $13.4M sold.

First Light Asset Management first reported a position in KROS in Q3 2021 and held it in 9 quarters. The position peaked at $35.8M in Q1 2022. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

First Light Asset Management reported no remaining Keros Therapeutics position as of Q4 2023 after selling out during the quarter.
First Light Asset Management sold 421,438 Keros Therapeutics shares in Q4 2023, an estimated $13.4M.
First Light Asset Management first reported a position in Keros Therapeutics in Q3 2021 and held it in 9 quarters.
First Light Asset Management's Keros Therapeutics position peaked at $35.8M in Q1 2022.
121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on First Light Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.